These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32042361)

  • 1. Successful treatment with rivaroxaban for an acute pulmonary thromboembolism in a patient with primary antiphospholipid antibody syndrome.
    Okamura G; Kawano H; Yoshida N; Koga S; Ikeda S; Ichinose K; Maemura K
    J Cardiol Cases; 2020 Feb; 21(2):79-81. PubMed ID: 32042361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
    Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
    J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome.
    Yagi S; Nishiyama S; Abe T; Sata M
    BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30635311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome.
    Williams B; Saseen JJ; Trujillo T; Palkimas S
    J Thromb Thrombolysis; 2022 Jul; 54(1):67-73. PubMed ID: 34817786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies.
    Bauersachs R; Langer F; Kalka C; Konstantinides S; Klamroth R; Oldenburg J; Schellong S; Scholz U; Stücker M; Lindhoff-Last E
    Vasa; 2019 Nov; 48(6):483-486. PubMed ID: 31621546
    [No Abstract]   [Full Text] [Related]  

  • 7. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
    Akwaa F; Spyropoulos AC
    Curr Med Res Opin; 2014 Nov; 30(11):2179-90. PubMed ID: 25105309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.
    Bauersachs R; Agnelli G; Gitt AK; Monreal M; Mismetti P; Willich SN; Laeis P; Fronk EM; Bramlage P; Cohen AT;
    Thromb Res; 2017 Sep; 157():181-188. PubMed ID: 28780343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.
    Dufrost V; Risse J; Reshetnyak T; Satybaldyeva M; Du Y; Yan XX; Salta S; Gerotziafas G; Jing ZC; Elalamy I; Wahl D; Zuily S
    Autoimmun Rev; 2018 Oct; 17(10):1011-1021. PubMed ID: 30103045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic storm in a 4-year-old boy with a thrombus in the right atrium.
    Ma JY; Zhang X; Li XF; He LJ; Ma N; Wei YY; Wu RH; Wang FY
    Int J Immunopathol Pharmacol; 2018; 32():2058738418778121. PubMed ID: 29798687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacoeconomic study of traditional anticoagulation versus direct oral anticoagulation for the treatment of venous thromboembolism in the emergency department.
    Law S; Ghag D; Grafstein E; Stenstrom R; Harris D
    CJEM; 2016 Sep; 18(5):340-8. PubMed ID: 27618975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome.
    Arora S; Nair S; Prabhu R; Avanthika C; Jhaveri S; Samayam S; Katta MR; Agarwal P
    Cureus; 2021 Oct; 13(10):e19009. PubMed ID: 34824926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
    Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
    Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid.
    Sugie M; Iizuka N; Shimizu Y; Ichikawa H
    Intern Med; 2015; 54(23):3051-6. PubMed ID: 26631891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.